The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are usually associated with loss of dopaminergic neurons. Loss of substantia nigra neurons and presence of Lewy body inclusions in some of the remaining neurons are the hallmark pathology seen in the final stages of the disease. Attempts to correlate Lewy body pathology to either cell death or severity of clinical symptoms, however, have not been successful. While the pathophysiology of the neurodegenerative process can hardly be explained by Lewy bodies, the clinical symptoms do indicate a degenerative process located at the presynapse resulting in a neurotransmitter deficiency. Recently it was shown that 90% or even more of alpha-synuclein aggregates in DLB cases were located at the presynapses in the form of very small deposits. In parallel, dendritic spines are retracted, whereas the presynapses are relatively preserved, suggesting a neurotransmitter deprivation. The same alpha-synuclein pathology can be demonstrated for PD. These findings give rise to the notion that not cell death but rather alpha-synuclein aggregate-related synaptic dysfunction causes the neurodegeneration. This opens new perspectives for understanding PD and DLB. If presynaptic alpha-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future. The disease may progress via trans-synaptical spread, suggesting that stem cell transplants are of limited use. Future therapies may focus on the regeneration of synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“It could be demonstrated that the presence of symptoms may be related to the involvement of defined regions as measured by the occurrence of Lewy bodies [47–49], supporting the observations that the a-synuclein aggregation pathology spreads through the brain involving anatomical structures sequentially [13].”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The discovery of mutations in the a-synuclein gene [77, 114, 156] and overexpression of a-synuclein [123] as being associated with Parkinson’s disease or dementia with Lewy bodies (DLB) strengthens the association between protein”
BackgroundParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 2×
“Tremor at rest, rigidity, akinesia/bradykinesia and postural instability are the four cardinal features in Parkinson’s disease [60].”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“association between the frequency and extension of tangles and Ab-plaques and the occurrence of the disease [55, 104], Terry et al.”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It was assumed that the cognitive impairment in AD is related to a synaptic failure [121, 124, 130].”
Background
Cited by
Items 201–300 of 664
Bellucci, A., Navarria, L., Zaltieri, M., Missale, C., & Spano, P. (2011) · Brain Research · doi:10.1016/j.brainres.2011.11.031 · Cited by 59
“…to the observation that in DLB 90% or even more α-synuclein aggregates are located at presynapses in the form of very small deposits, suggesting that not cell death, but α-synuclein aggregaterelated synaptic dysfunctions may cause the neurodegeneration (Kramer et al., 2008; Schulz-Schaeffer, 2010).”
InfluentialSynucleinopathies: common features and hippocampal manifestations
Yang, W., & Yu, S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2411-y · Cited by 53
Santpere, G., Garcia‐Esparcia, P., Andrés‐Benito, P., Lorente-Galdós, B., Navarro, A., & Ferrer, I. (2017) · Brain Pathology · doi:10.1111/bpa.12511 · Cited by 53
“Abnormal folding and oligomerization and formation of certain types of aggregates may directly produce synaptic damage, and may do so indirectly by exerting toxicity on mitochondria, lysosomes and cytoskeleton (56, 74, 85).”
BackgroundMorphological basis of Parkinson disease-associated cognitive impairment: an update
Jellinger, K. A. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02522-4 · Cited by 55
“Due to the ubiquitous deposition of αSyn in the central nervous system with high enrichment in presynaptic terminals, PD is denoted a synucleinopathy (Uversky 2009), showing specific synaptic pathology of αSyn aggregation (Schulz-Schaeffer 2010).”
BackgroundBencsik, A., Muselli, L., Leboidre, M., Lakhdar, L., & Baron, T. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000137 · Cited by 48
Linking α-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson’s disease
Kulkarni, A. S., Burns, M. R., Brundin, P., & Wesson, D. W. (2022) · Brain Communications · doi:10.1093/braincomms/fcac165 · Cited by 49
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases
Jensen, N. M., Vitic, Z., Antorini, M. R., Viftrup, T. B., Parkkinen, L., & Jensen, P. H. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02871-w · Cited by 49
Khotimah, H., Ali, M., Sumitro, S. B., & Widodo, M. A. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2015.07.024 · Cited by 55
N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases
Martínez, M. (2022) · Antioxidants · doi:10.3390/antiox11020416 · Cited by 48
“Recent data shows that the accumulation of α-synuclein starts as micro-aggregates of the protein at the presynapse, impairing neurotransmitter vesicle trafficking and discharge in dopaminergic neurons [168,169].”
BackgroundMild Cognitive Impairment in Parkinson’s Disease: A Review of Current Concepts
Palavra, N. C., Naismith, S. L., & Lewis, S. J. G. (2013) · Neurology Research International · doi:10.1155/2013/576091 · Cited by 56
Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Gomperts, S. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0472-6 · Cited by 50
Pradhan, S., & Andreasson, K. I. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.008 · Cited by 49
Cooperative inhibition of SNARE-mediated vesicle fusion by α-synuclein monomers and oligomers
Yoo, G., Yeou, S., Son, J. B., Shin, Y., & Lee, N. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-90503-0 · Cited by 46
So, Y.-J., Lee, J.-U., Yang, G.-S., Yang, G., Kim, S. W., Lee, J., & Kim, J.-U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021071 · Cited by 46
α-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling
Medeiros, A. T., Soll, L. G., Tessari, I., Bubacco, L., & Morgan, J. R. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00388 · Cited by 42
“α-Synuclein overexpression and aggregation are also commonly observed in other neurodegenerative disorders, including Lewy body dementia (LBD), multiple systems atrophy and some variants of Alzheimer’s disease (Schulz-Schaeffer, 2010; Moussaud et al., 2014; Ingelsson, 2016).”
BackgroundThe application of positron emission tomography (PET) imaging in CNS drug development
Suridjan, I., Comley, R. A., & Rabiner, E. A. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9967-0 · Cited by 45
“Importantly in PD, the link between α-SYN aggregation and synaptic dysfunction opens up a completely new approach towards understanding these diseases and treatment options (Schulz-Schaeffer 2010).”
BackgroundGenetically engineered animal models of Parkinson's disease: From worm to rodent
Breger, L. S., & Armentero, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14300 · Cited by 47
Diniz, L. P., Matias, I., Araujo, A. P. B., Garcia, M. N., Barros‐Aragão, F. G. Q., Alves‐Leon, S. V., de Souza, J. M., Foguel, D., Figueiredo, C. P., Braga, C., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14710 · Cited by 41
VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
van Steenoven, I., Noli, B., Cocco, C., Ferri, G., Oeckl, P., Otto, M., Koel‐Simmelink, M. J. A., Bridel, C., van der Flier, W. M., Lemstra, A. W., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194674 · Cited by 47
Dysfunction of Synaptic Vesicle Endocytosis in Parkinson’s Disease
Zou, L., Tian, Y., & Zhang, Z. (2021) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2021.619160 · Cited by 44
“…protein 7; ATP, adenosine triphosphate. be the earliest feature of the disease (Lee et al., 2000; Serra et al., 2002; Dauer and Przedborski, 2003; Shin et al., 2008; Li L.H. et al., 2009; Qing et al., 2009; Cheng et al., 2010; Kagi et al., 2010; Schulz-Schaeffer, 2010; Peelaerts et al., 2015).”
BackgroundRoth, J. A. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.08.006 · Cited by 48
“Aggregated a-synuclein is a major constituent of Lewy bodies associated with Parkinsonism and mutations are linked with familial Parkinson’s disease (Spillantini et al., 1997; Baba et al., 1998; Schulz-Schaeffer, 2010).”
BackgroundWeil, R. S., Lashley, T., Brás, J., Schrag, A. E., & Schott, J. M. (2017) · F1000Research · doi:10.12688/f1000research.11725.1 · Cited by 49
Baicalin Represses C/EBPβ via Its Antioxidative Effect in Parkinson’s Disease
Lei, K., Shen, Y., He, Y., Zhang, L., Zhang, J., Tong, W., Xu, Y., & Jin, L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8951907 · Cited by 48
“α-Synuclein accumulates in Lewy bodies, which is the hallmark in PD pathology and leads to neurodegeneration and the progression of the clinical symptoms [7].”
BackgroundCritical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders
Nouraei, N., Mason, D. M., Miner, K. M., Carcella, M. A., Bhatia, T. N., Dumm, B. K., Soni, D., Johnson, D. A., Luk, K. C., & Leak, R. K. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.017 · Cited by 44
“Future studies on protein levels and posttranslational changes in other presynaptic and postsynaptic markers are also warranted, as some have argued that presynapses are preserved in dementia with Lewy bodies whereas dendritic spines are retracted (Schulz-Schaeffer, 2010).”
BackgroundInfluentialBoiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells · doi:10.3390/cells10010038 · Cited by 42
Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease
de Schipper, L. J., van der Grond, J., Marinus, J., Henselmans, J. M. L., & van Hilten, J. J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.012 · Cited by 42
“However, the functional consequences of α-synuclein aggregation in the brain are unclear and Braak stages are not related to clinical severity of PD (Schulz-Schaeffer, 2010).”
Sepúlveda, D., Cisternas-Olmedo, M., Arcos, J., Nassif, M., & Vidal, R. L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.805087 · Cited by 42
“These aggregates of the amyloid type are called Lewy bodies and are constituted mainly by oligomers of α-syn and ubiquitin (Spillantini et al., 1998; Schulz-Schaeffer, 2010).”
BackgroundGenomics studies on musical aptitude, music perception, and practice
Järvelä, I. E. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13620 · Cited by 43
Klobušiaková, P., Mareček, R., Fousek, J., Výtvarová, E., & Rektorová, I. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180834 · Cited by 43
Antoniou, N., Prodromidou, K., Kouroupi, G., Boumpoureka, I., Samiotaki, M. K., Panayotou, G., Xilouri, M., Kloukina, I., Stefanis, L., Grailhe, R., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00278-y · Cited by 43
Impact of DHA intake in a mouse model of synucleinopathy
Coulombe, K., Kerdiles, O., Tremblay, C., Emond, V., Lebel, M., Boulianne, A.-S., Plourde, M., Cicchetti, F., & Calon, F. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.12.002 · Cited by 38
“This is further in line with neuropathological observations indicating that an important proportion of αSyn aggregates are localized in axons in human synucleinopathies, leading to the suggestion that αSyn induces synaptic dysfunction before neurodegeneration (Lam et al., 2011; Schulz-Schaeffer, 2010; Wu et al., 2010).”
BackgroundResultLin, C., Cheng, Y., Li, H., Chiu, P., Chang, Y., Ho, Y., & Lai, T. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.10.009 · Cited by 40
“…α-synuclein (αSyn), a 140-amino soluble protein encoded by the SNCA gene abundantly expressed in the central nervous system (Kim et al., 2014). αSyn is likely to play a role in membrane stability and neuronal plasticity; however, its exact function remains largely unknown (Schulz-Schaeffer, 2010).”
The End Is the Beginning: Parkinson’s Disease in the Light of Brain Imaging
Bellucci, A., Antonini, A., Pizzi, M., & Spano, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00330 · Cited by 42
“Synaptic α-synuclein microaggregation occurs in the early stages of the degenerative process and in the post-mortem brain of PD patients the load of α-synuclein at terminals is several orders of magnitude higher than its content within LB (Schulz-Schaeffer, 2010).”
BackgroundThe Evolution-Driven Signature of Parkinson’s Disease
Diederich, N. J., Uchihara, T., Grillner, S. E., & Goetz, C. G. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.05.001 · Cited by 42
“Thus, the predominant role of aSyn pathology with only secondarily occurring cell death is most evident, whereas neuronal count, which represents only the local density of neurons, provides little insight into pathological interactions between aSyn and mitochondria [64].”
Longitudinal diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease
Firbank, M. J., Watson, R., Mak, E., Aribisala, B., Barber, R., Colloby, S. J., He, J., Blamire, A. M., & O'Brien, J. T. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.01.003 · Cited by 38
“In contrast, the lack of such an association in DLB is consistent with synaptic dysfunction rather than cell loss as a key feature of the disorder, possibly caused by presynaptic accumulation of oligomeric alpha-synuclein [20].”
BackgroundAssociated and predictive factors of depressive symptoms in patients with Parkinson’s disease
Zhu, K., van Hilten, J. J., & Marinus, J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8130-3 · Cited by 48
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
SV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
“This study, along with others, established an association between SV2C and LBD, underscoring the need for the development of a PET tracer targeting SV2C.”
BackgroundInfluentialWang, C., Wang, J., Zhu, Z., Hu, J., & Lin, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1421076 · Cited by 47
Kuang, Y., Mao, H., Huang, X., Chen, M., Dai, W. H., Gan, T., Wang, J., Sun, H., Lin, H., Liu, Q., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00449-2 · Cited by 41
Sepúlveda, D., Grünenwald, F., Vidal, A., Troncoso-Escudero, P., Cisternas-Olmedo, M., Villagra, R., Vergara, P., Aguilera, C., Nassif, M., & Vidal, R. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-05941-1 · Cited by 41
Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses
Banks, S. M. L., Medeiros, A. T., McQuillan, M., Busch, D. J., Ibarraran-Viniegra, A. S., Roy, S., Sousa, R., Lafer, E. M., & Morgan, J. R. (2020) · eNeuro · doi:10.1523/eneuro.0448-19.2020 · Cited by 41
“Perhaps as a consequence, synaptic aggregation of α-synuclein is highly correlated with cognitive deficits in some DLB and PD patients (Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010; Ingelsson, 2016).”
BackgroundAkhtar, A., Singh, S., Kaushik, R., Awasthi, R., & Behl, T. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102289 · Cited by 40
Alteration in Synaptic Junction Proteins following Traumatic Brain Injury
Merlo, L., Cimino, F., Angileri, F. F., Torre, D. L., Conti, A., Cardali, S. M., Saija, A., & Germanò, A. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2014.3385 · Cited by 40
The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review
Spano, M., Signorelli, M., Vitaliani, R., Aguglia, E., & Giometto, B. (2015) · Functional Neurology · doi:10.11138/fneur/2015.30.3.151 · Cited by 43
Fiorini, M. R., Dilliott, A. A., Thomas, R. A., & Farhan, S. M. K. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04124-5 · Cited by 41
Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease
Koehler, N. K. U., Stransky, E., Shing, M., Gaertner, S., Meyer, M., Schreitmüller, B., Leyhe, T., Laske, C., Maetzler, W., Kahle, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064649 · Cited by 35
“and deposit in the nervous system in the form of oligomers or insoluble amyloid [32–34].”
BackgroundAging of perennial cells and organ parts according to the programmed aging paradigm
Libertini, G., & Ferrara, N. (2016) · AGE · doi:10.1007/s11357-016-9895-0 · Cited by 39
“In these places, there is neuronal degeneration, but it has been proposed that Lewy bodies could be a protection against harmful factors and not the cause of cell death (Obeso et al. 2010; Schulz-Schaeffer 2010).”
BackgroundRegional functional synchronizations in dementia with Lewy bodies and Alzheimer's disease
Peraza, L. R., Colloby, S. J., Deboys, L., O'Brien, J. T., Kaiser, M., & Taylor, J. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000429 · Cited by 37
“…node degree between both patient groups showing lower node degree in temporal cortices in AD and higher node degree in parietal and occipital cortices in DLB, and which might be related to aetiological divergences between the dieases, e.g. amyloid and synuclein pathologies (Schulz-Schaeffer, 2010).”
BackgroundMarquié, M., Locascio, J. J., Rentz, D. M., Becker, J. A., Hedden, T., Johnson, K. A., Growdon, J. H., & Gomperts, S. N. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0052-7 · Cited by 40
“Other neuropathological factors, such as alpha-synuclein deposition [1], synaptic dysfunction [60], amyloid burden [40], and impairment of other neuromodulator systems [61], must make DLB patients susceptible to the impact of dopamine dysfunction.”
BackgroundCerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease
Johar, I., Mollenhauer, B., & Aarsland, D. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2016.12.001 · Cited by 39
Pfanner, T., Henri‐Bhargava, A., & Borchert, S. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.251 · Cited by 38
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
Iarkov, A., Mendoza, C., & Echeverría, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.665820 · Cited by 39
“The progressive appearance of protein deposits called Lewy bodies often accompanies the loss of dopaminergic neurons in various brain regions (Schulz-Schaeffer, 2010; Mehra et al., 2019).”
BackgroundThe Role of Rab Proteins in Parkinson’s Disease Synaptopathy
Bellucci, A., Longhena, F., & Spillantini, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10081941 · Cited by 37
Ray, N. J., & Strafella, A. P. (2012) · Movement Disorders · doi:10.1002/mds.25173 · Cited by 35
Topography of cortical thinning in the Lewy body diseases
Ye, R., Touroutoglou, A., Brickhouse, M. J., Katz, S. R., Growdon, J. H., Johnson, K. A., Dickerson, B. C., & Gomperts, S. N. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102196 · Cited by 35
Tai, C.-H., Bellesi, M., Chen, A.-C., Lin, C.-L., Li, H.-H., Lin, P.-J., Liao, W.-C., Hung, C.-S., Schwarting, R. K., & Ho, Y.-J. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.020 · Cited by 34
Tönges, L., Planchamp, V., Koch, J. C., Herdegen, T., Bähr, M., & Lingor, P. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9519-1 · Cited by 36
“Schulz-Schaeffer 2010 ) and may be the substrate of regenerative approaches.”
BackgroundRavid, R., & Ferrer, I. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08518.x · Cited by 36
Alpha- and beta-synuclein expression in Parkinson disease with and without dementia
Beyer, K., Ispierto, L., Latorre, P., TOLOSA, E. S., & Ariza, A. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.049 · Cited by 34
“These changes comprise the relative increase of AS and could enhance further AS oligomerization/aggregation with forming of small dendritic AS aggregates followed by synaptic loss [13,32].”
BackgroundImportance of nondopaminergic features in evaluating disease severity of Parkinson disease
van der Heeden, J. F., Marinus, J., Martínez‐Martín, P., & van Hilten, J. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000087 · Cited by 34
SUMOylation of Alpha-Synuclein Influences on Alpha-Synuclein Aggregation Induced by Methamphetamine
Zhu, L., Qiao, H., Chen, L., Sun, L., Hui, J., Lian, Y., Xie, W., Ding, J., Meng, Y., Zhu, B., et al. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00262 · Cited by 35
“They visualized tiny α-syn was rich in the cortex of neurodegenerative diseases patients (Schulz-Schaeffer, 2010).”
BackgroundMitochondrial Aconitase and Its Contribution to the Pathogenesis of Neurodegenerative Diseases
Padalko, V., Posnik, F., & Adamczyk, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189950 · Cited by 34
“Protein misfolding also occurs in PD [128].”
BackgroundNew insights into atypical parkinsonism
Wenning, G. K., Krismer, F., & Poewe, W. H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283480569 · Cited by 33
The ubiquitin-proteasome system and microvascular complications of diabetes.
Aghdam, S. Y., & Sheibani, N. (2013) · PubMed Central · Cited by 39
Iba, M., Kim, C., Florio, J. B., Mante, M., Adame, A., Rockenstein, E. M., Kwon, S., Rissman, R. A., & Masliah, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00286 · Cited by 34
“…the progressive accumulation of α-syn has been associated with synaptic loss in DLB/PD patients and α-syn Tg animal models (Revuelta et al., 2008; Schulz-Schaeffer, 2010; Ubhi et al., 2010; Overk and Masliah, 2014; Rockenstein et al., 2014), our study suggests that alterations in p38γ levels…”
BackgroundRetractedTransmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson’s disease
Thomzig, A., Wagenführ, K., Pinder, P., Joncic, M., Schulz‐Schaeffer, W., & Beekes, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02312-4 · Cited by 35
Self-citationSoll, L. G., Eisen, J. N., Vargas, K. J., Medeiros, A. T., Hammar, K. M., & Morgan, J. R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00405 · Cited by 34
“In these diseases, α-synuclein aggregates throughout neurons, including axons and synapses, leading to cellular toxicity and neurodegeneration (Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010; Scott et al., 2010; Burre et al., 2018; Sulzer and Edwards, 2019).”
BackgroundA glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Hartlage‐Rübsamen, M., Bluhm, A., Moceri, S., Machner, L., Köppen, J., Schenk, M., Hilbrich, I., Holzer, M., Weidenfeller, M., Richter, F., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02349-5 · Cited by 35
Ciafone, J., Thomas, A. J., Durcan, R., Donaghy, P. C., Hamilton, C. A., Lawley, S., Roberts, G., Colloby, S. J., Firbank, M., Allan, L. M., et al. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721001181 · Cited by 35
Parkinson's disease and mitochondrial gene variations: A review
Andalib, S., Vafaee, M. S., & GJEDDE, A. H. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.067 · Cited by 34
Impaired synaptic function is linked to cognition in Parkinson's disease
Selnes, P., Stav, A. L., Johansen, K. K., Bjørnerud, A., Coello, C. S., Auning, E., Kalheim, L. F., Almdahl, I. S., Hessen, E., Zetterberg, H., et al. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.446 · Cited by 33
From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders
Duranti, E., & Villa, C. (2024) · Biology · doi:10.3390/biology13090719 · Cited by 34
Neurodegenerative changes initiated by presynaptic dysfunction
Yasuda, T., Nakata, Y., Choong, C., & Mochizuki, H. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-16 · Cited by 33
“impairment in DLB [5,6].”
BackgroundInfluentialExosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications
Ouerdane, Y., Hassaballah, M. Y., Nagah, A., Ibrahim, T. M., Mohamed, H. A. H., El-Baz, A., & Attia, M. S. (2022) · Pharmaceuticals · doi:10.3390/ph15010076 · Cited by 33
“These bodies appear after the depletion of dopaminergic neurons at the substantia nigra pars compacta [7,8], explaining why α-syn gene overexpression or mutation is strongly associated with PD and dementia with Lewy bodies accumulation [9,10].”
BackgroundSynaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
Gutierrez, B. A., & Limón, A. (2022) · Biomedicines · doi:10.3390/biomedicines10071743 · Cited by 35
Sae‐ung, K., Uéda, K., Govitrapong, P., & Phansuwan‐Pujito, P. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00927.x · Cited by 33
“At present, it is recognized to be the major protein component characteristic of several neurodegenerative disorders [5, 6], together referred to as synucleinopathies.”
BackgroundLonghena, F., Faustini, G., Missale, C., Pizzi, M., & Bellucci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061611 · Cited by 31
Neuropathology of Parkinson’s Disease
Jellinger, K. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_2 · Cited by 35
“Loss of neurons might be an epiphenomenon after the loss of synapses, defi ning PD as a “synaptopathy” [ 53 , 145 ].”
BackgroundThe Role of Atypical Chemokine Receptors in Neuroinflammation and Neurodegenerative Disorders
Lindsay, H. G., Hendrix, C. J., Murcia, J. D. G., Haynie, C., & Weber, K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216493 · Cited by 30
The role of the protein–RNA recognition code in neurodegeneration
Nahálka, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03096-3 · Cited by 32
Cognitive Training in Parkinson’s Disease: A Review of Studies from 2000 to 2014
Glizer, D., & MacDonald, P. A. (2016) · Parkinson s Disease · doi:10.1155/2016/9291713 · Cited by 33
O-GlcNAcylation of Neuronal Proteins: Roles in Neuronal Functions and in Neurodegeneration
Lagerlöf, O., & Hart, G. W. (2014) · Advances in neurobiology · doi:10.1007/978-1-4939-1154-7_16 · Cited by 32
Parkinson’s disease and translational research
Dinter, E., Saridaki, T., Diederichs, L., Reichmann, H., & Falkenburger, B. H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00223-0 · Cited by 31
Zhang, Y., Ding, C., Li, C., & Wang, X. (2021) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.08.008 · Cited by 29
Faustini, G., Longhena, F., Masato, A., Bassareo, V., Frau, R., Klingstedt, T., Shirani, H., Brembati, V., Parrella, E., Vezzoli, M., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.021 · Cited by 29
α-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation
Takei, Y., Oguchi, K., Koshihara, H., Hineno, A., Nakamura, A., & Ohara, S. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.10.024 · Cited by 29
“Because α-synuclein is known to be localized to the presynaptic terminal [13], interaction of mutant SOD1 protein and α-synuclein across axosomatic synapses may have occurred, triggering α-synuclein aggregation.”
BackgroundPKM2 aggregation drives metabolism reprograming during aging process
Bie, J., Li, R., Li, Y., Chen, S., Chen, Z., Zhang, T., Tang, Z., Su, L., Zhu, L., Wang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50242-y · Cited by 31
Synaptic Protein Alterations in Parkinson’s Disease
Pienaar, I. S., Burn, D. J., Morris, C. M., & Dexter, D. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8226-9 · Cited by 32
Jiang, M. H., Tu, H., Zhang, K., Zhang, W., Yu, W., Xu, J., Tan, E., Guo, K., & Zeng, L. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105313 · Cited by 29
“Parkinson’s disease (PD) is a common progressive neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the substantia nigra of the midbrain and the accumulation of Lewy body aggregates (Kim et al., 2002; Schulz-Schaeffer, 2010; Trojanowski et al., 1998).”
BackgroundWallace, J. N., Crockford, Z. C., Román‐Vendrell, C., Brady, E. B., Hoffmann, C., Vargas, K. J., Potcoava, M. C., Wegman, M. E., Alford, S. T., Milovanović, D., et al. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-07-0269 · Cited by 31
Postmortem Studies of Fetal Grafts in Parkinson’s Disease: What Lessons Have We Learned?
Li, J., & Li, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666675 · Cited by 28
“…al., 2012) and from the peripheral tissue to the brain (Braak et al., 2003; Goedert et al., 2010; Holmqvist et al., 2014), inducing multiple aspects of cell dysfunction (Schulz-Schaeffer, 2010; Winslow et al., 2010; Subramaniam and Chesselet, 2013; Wong and Krainc, 2017), such as dopamine release.”
BackgroundHabib, R., Noureen, N., & Nadeem, N. (2018) · Current Genomics · doi:10.2174/1389202918666171005100549 · Cited by 30
Lim, S. H., Ferdousi, M., Kalteniece, A., Kass‐Iliyya, L., Petropoulos, I. N., Malik, R. A., Kobylecki, C., & Silverdale, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-76768-x · Cited by 27
Böttner, M., Fricke, T., Müller, M., Barrenschee, M., Deuschl, G., Schneider, S. A., Egberts, J., Becker, T., Fritscher‐Ravens, A., Ellrichmann, M., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2015.04.015 · Cited by 27
“However, the pathophysiology of the neurodegenerative process can hardly be explained by the presence and frequency of Lewy bodies (Schulz-Schaeffer, 2010).”
Self-citationKaur, T., Sidana, P., Kaur, N., Choubey, V., & Kaasik, A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01549-1 · Cited by 27
“Aggregation of α-syn at the presynapses in the form of very small deposits is the prime reason of neurodegeneration and marks the major hallmark of PD (Schulz-Schaeffer 2010).”
Chatterjee, M., van Steenoven, I., Huisman, E., Oosterveld, L. P., Berendse, H. W., van der Flier, W. M., del Campo, M., Lemstra, A. W., van de Berg, W. D. J., & Teunissen, C. E. (2020) · Biomolecules · doi:10.3390/biom10081177 · Cited by 26
Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
Andersen, K. B., Hansen, A. K., Knudsen, K., Schacht, A. C., Damholdt, M. F., Brooks, D. J., & Borghammer, P. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.007 · Cited by 27
CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25
“burden of αSyn pathology at synapses.(44) In the future, development of in vivo αSyn markers combined with longitudinal tracking might disentangle how CSF Ng levels change with accumulating AD and αSyn pathology.”
BackgroundJensen, N. M., Fu, Y., Betzer, C., Li, H., Elfarrash, S., Shaib, A., Krah, D., Vitic, Z., Reimer, L., Gram, H., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00841-9 · Cited by 27
“A prime candidate forits principal location isthe presynaptic and axonal compartments, which are believed to be the earliest affected parts of the neurons 64,70 – 73 .”
Metadata
- Authors
- Schulz-Schaeffer, W. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-06-20
- Volume
- 120
- Issue
- 2
- Pages
- 131-143
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2892607
- OpenAlex
- W2033827101
- Cited by
- 627
- References
- 165
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 45 · 2023: 24 · 2022: 43 · 2021: 48 · 2020: 48 · 2019: 41 · 2018: 40 · 2017: 35 · 2016: 36 · 2015: 29 · 2014: 41 · 2013: 36 · 2012: 35
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Funders
- Volkswagen Foundation (ZN 2168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein aggregation, Lewy bodies, dementia with Lewy bodies, Parkinson's disease, Parkinson's disease dementia, presynaptic dysfunction, synaptic pathology, neurotransmitter deficiency, neurodegeneration, trans-synaptic spread, stem cell transplantation, synapse regeneration
- MeSH terms
- Animals, Brain, Parkinson Disease, Synapses, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.